Oncode Accelerator Summit 2024
Accelerate to Outsmart Cancer
For the first time since the official start of the Oncode Accelerator program in September 2023, cancer researchers, drug developers, investors, patient advocates, and representatives from additional stakeholders gathered in Amsterdam to discuss how to collectively accelerate the development of new cancer therapies.
Arnoud Huisman, CEO and member of the board of the Oncode Accelerator foundationWe are here to collaboratively work on accelerating oncology drug development. To outsmart cancer and impact lives. We share the same goal and are all part of the same ecosystem.
Innovate to accelerate
The Oncode Accelerator Summit started off with three presentations highlighting the innovations which aim to accelerate the development of new cancer therapies.
Changing the paradigm: The importance of well-defined patient cohorts in early stages of drug development.
Miriam Koopman, Professor & Internist-Oncologist, University Medical Center Utrecht and lead of the Innovation Platform well-defined Patient Cohorts at Oncode Accelerator
Organoids as innovative patient-derived tools in preclinical drug development.
Jarno Drost, group leader at the Princess Máxima Center for Pediatric Oncology and Oncode Institute and lead of the Innovation Platform Organoids at Oncode Accelerator
Data-driven Drug Discovery: How AI supports decision making and de-risking in oncology and beyond.
Andreas Bender, Incoming Professor for Machine Learning in Medicine, Khalifa University, Abu Dhabi, UAE and Chief Technology Officer, Pangea Bio Ltd
Building bridges
During the second part of the Oncode Accelerator Summit, the focus was on the need to collaborate in order to bridge the gap between preclinical stages of the drug development pipeline and patients in the clinic.
Break the bubble to make impact: Leaving our comfort zone to accelerate technological and societal impact.
Maurice van Tilburg, retiring Director of the National Growth Fund at the Dutch Ministry of Economic Affairs
Could investors help cure cancer?
René Kuijten, Partner & Head of EQT Life Sciences and member of the Supervisory Board of Oncode Institute and Oncode Accelerator
Innovate, integrate and collaborate: Accelerating the development of Biologics therapeutics for oncology patients.
Debby Vermeer-Kruijsen, independent consultant at DVK Biotech and co-lead of the Oncode Accelerator Workstream Biologics
Accelerate to outsmart cancer
The mission of Oncode Accelerator is to collaboratively optimize and accelerate the development of new cancer therapies for the benefit of patients of all ages, and to eventually outsmart cancer and impact lives. The last session at the Oncode Accelerator Summit provided a stage to showcase our progress to date and featured a keynote by Peter Kapitein, who shared his personal views and perspectives as a patient advocate.
The Oncode Accelerator path to outsmart cancer and impact lives: achievements and next steps.
Friso Smit, Chief Operational Officer and member of the Board of Directors, Oncode Accelerator Foundation
Medicines that don’t reach the patient, don’t cure.
Peter Kapitein, cancer survivor, patient advocate, and founder of Inspire2Live and Alpe d'HuZes
Photo Credits: Seth Carnill
Interested in our next events?
Please subscribe to our mailing list, to receive invites to events and webinars and more news from Oncode Accelerator.